{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:54:20Z","timestamp":1793195660893,"version":"4.5.0"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Urate lowering therapies (ULTs) are primarily used to manage hyperuricemia (HUA), which refers to an increase in serum uric acid (SUA) levels. SUA is an important marker for assessing kidney function in patients complicated with chronic kidney disease (CKD). Recent studies revealed a close relationship between SUA and lipid metabolism. We aim to investigate the impact of ULTs on kidney function and lipid profiles in CKD patients, and further explore the sex-specific ULTs effects on lipid profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We conducted a multicenter, prospective observational cohort study, enrolled n=200 patients aged between 20 and 80 years old with stages 3\/4 CKD. Patients were divided into two groups: the ULT group (n=94) who were receiving febuxostat or allopurinol, and the Non-ULT group (n=106) who were receiving their conventional CKD therapy, the study employed clinically indicated allocation. ULT initiation was based on physician judgment per guidelines persistent HUA with SUA \u22657 mg\/dL in males and \u22656 mg\/dL in females with CKD progression risk factors. Models adjusted for all collected confounders, renal function including estimated glomerular filtration rate (eGFR), serum creatinine (Scr), blood urea nitrogen (BUN), and SUA, and lipid profiles including high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), triglyceride (TG), and total cholesterol (TC). Results remained consistent in sensitivity analyses stratifying by baseline characteristics. Subgroups were further analyzed based on sex, to evaluate sex-specific differences in lipid metabolism related to ULTs. All participants went through clinical assessment before and after treatment and were followed for 12 consecutive months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      LDL-c significantly decreased in the ULT group compared to the Non-ULT group after 12 months of observation (2.14 \u00b1 0.32 vs. 2.42 \u00b1 0.32 [95% CI: -0.36 to -0.18],\n                      <jats:italic>P&amp;lt;0,001<\/jats:italic>\n                      ). Similarly, TC and TG were significantly decreased in the ULT group compared to the Non-ULT group after 12 months of observation (4.18 \u00b1 0.44 vs. 4.47 \u00b1 0.39 [95% CI: -0.40 to -0.16],\n                      <jats:italic>P&amp;lt;0,001<\/jats:italic>\n                      ) for TC, and (2.43 \u00b1 0.62 vs. 2.63 \u00b1 0.58 [95% CI: -0.37 to -0.03],\n                      <jats:italic>P&amp;lt;0,016<\/jats:italic>\n                      ) for TG. Moreover, HDL-c increased significantly in the ULT group compared to the Non-ULT group (1.41 \u00b1 0.13 vs. 1.23 \u00b1 0.15 [95% CI: 0.13 to 0.21],\n                      <jats:italic>P&amp;lt;0.001<\/jats:italic>\n                      ). The sex-specific ULT on lipid profiles exhibited a greater reduction in LDL-c in males by (-0.28 mmol\/L [95% CI: -0.32 to -0.14],\n                      <jats:italic>P&amp;lt;0.001<\/jats:italic>\n                      ), and a more pronounced increase in HDL-c levels by (+0.23 mmol\/L [95% CI: 0.07 to 0.18],\n                      <jats:italic>P&amp;lt;0.001<\/jats:italic>\n                      ). A significant correlation was observed Pre- and Post-treatment between SUA and LDL-c\/HDL-c, Post-treatment LDL-c (R=0.2942, R\u00b2=0.2639, 95% CI: [0.0974 to 0.4689],\n                      <jats:italic>P&amp;lt;0.0040)<\/jats:italic>\n                      , Post-treatment HDL-c (R=-0.3935, R\u00b2=0.1548, 95% CI: [-0.5521 to -0.2074],\n                      <jats:italic>P&amp;lt;0.0001<\/jats:italic>\n                      ). SUA significantly decreased in the ULT group compared to the Non-ULT group after 12 months of treatment (398.55 \u00b1 45.48 vs. 456.66 \u00b1 38.23 [95% CI: -69.78 to -46.42],\n                      <jats:italic>P&amp;lt;0.001).<\/jats:italic>\n                      Similarly, eGFR slightly improved in the ULT group compared to the Non-ULT after 12 months of treatment (40.83 \u00b1 7.50 vs. 34.43 \u00b1 7.68 [95% CI: 4.32 to 8.51],\n                      <jats:italic>P&amp;lt;0.001).<\/jats:italic>\n                      These results indicate the renoprotective effects of ULTs in CKD patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this cohort study of non-dialysis CKD patients, ULT use was associated with improved lipid profiles reduced LDL-c, TG, and TC; increased HDL-c, with greater HDL-c elevation and LDL-c reduction in males. ULTs exposure also correlated with attenuated CKD progression. These findings suggest potential interactions between SUA and lipid metabolism, highlighting ULTs\u2019 possible role in managing dyslipidemia and renal function decline in pre-dialysis CKD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1592290","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T04:19:22Z","timestamp":1757391562000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Assessment of urate-lowering therapies on lipid metabolism and kidney function in non-dialysis chronic kidney disease patients: 12 months multicenter cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"Yousuf Abdulkarim","family":"Waheed","sequence":"first","affiliation":[{"name":"Department of Nephrology, Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, China"]},{"name":"Clinical Research Center for Kidney Disease Xuzhou Medical University","place":["Xuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanhuan","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Fengxian People\u2019s Hospital","place":["Xuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, the Second Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifaa","family":"Almayahe","sequence":"additional","affiliation":[{"name":"Medical College, University of Fallujah","place":["AL Anbar, Iraq"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Bishdary","sequence":"additional","affiliation":[{"name":"Central Michigan University College of Medicine","place":["Mount Pleasant, MI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthick Kumaran","family":"Munisamy Selvam","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Muhammad","family":"Farrukh","sequence":"additional","affiliation":[{"name":"Medical College, Xuzhou Medical University","place":["Xuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, China"]},{"name":"Clinical Research Center for Kidney Disease Xuzhou Medical University","place":["Xuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Disheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, China"]},{"name":"Clinical Research Center for Kidney Disease Xuzhou Medical University","place":["Xuzhou, China"]},{"name":"Department of Internal Medicine and Diagnostics, Xuzhou Medical University","place":["Xuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinglei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Nephrology, the Second Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, China"]},{"name":"Clinical Research Center for Kidney Disease Xuzhou Medical University","place":["Xuzhou, China"]},{"name":"Department of Internal Medicine and Diagnostics, Xuzhou Medical University","place":["Xuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008010080","article-title":"Elevated uric acid increases the risk for kidney disease","volume":"19","author":"Obermayr","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-023-00424-1","article-title":"A therapeutic target for CKD: activin A facilitates TGF\u03b21 profibrotic signaling","volume":"28","author":"Soomro","year":"2023","journal-title":"Cell Mol Biol Lett"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-018-1153-8","article-title":"Higher serum levels of uric acid are associated with a reduced insulin clearance in non-diabetic individuals","volume":"55","author":"Fiorentino","year":"2018","journal-title":"Acta Diabetol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2020.340","article-title":"Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease","volume":"36","author":"Waheed","year":"2021","journal-title":"Korean J Intern Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.70000","article-title":"The role of hyperuricemia in the progression of end-stage kidney disease and its molecular prospective in inflammation and cardiovascular diseases: A general review","author":"Waheed","year":"2025","journal-title":"Ther Apher Dial"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/nu11081736","article-title":"Uric acid and plant-based nutrition","volume":"11","author":"Jak\u0161e","year":"2019","journal-title":"Nutrients"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3760\/cma.j.issn.1000-6699.2020.01.001","article-title":"Chinese society of endocrinology. Guidelines for the diagnosis and management of hyperuricemia and gout in China (2019)","volume":"2020","year":"2020","journal-title":"Chin J Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/762820","article-title":"Prevalence of hyperuricemia and gout in mainland China from 2000 to 2014: A systematic review and meta-analysis","volume":"2015","author":"Liu","year":"2015","journal-title":"BioMed Res Int"},{"key":"B9","doi-asserted-by":"publisher","first-page":"26675","DOI":"10.1038\/s41598-024-76970-1","article-title":"Association of serum uric acid with all-cause and cardiovascular mortality in cardiovascular disease patients","volume":"14","author":"Lv","year":"2024","journal-title":"Sci Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.11817\/j.issn.1672-7347.2023.220539","article-title":"A cohort study on the correlation between serum uric acid trajectory and the progression of renal function in patients with Type 2 diabetes mellitus","volume":"48","author":"Pan","year":"2023","journal-title":"Zhong nan da xue xue bao. Yi xue ban = J Cent South University. Med Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/j.1523-1755.2005.00459.x","article-title":"Correlation of uric acid and urinary albumin excretion rate in patients with type 2 diabetes mellitus in Taiwan","volume":"68","author":"Tseng","year":"2005","journal-title":"Kidney Int"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(82)91513-6","article-title":"Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease","volume":"2","author":"Moorhead","year":"1982","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1542-4758.2006.01168.x","article-title":"Mechanisms of dyslipidemia of chronic renal failure","volume":"10","author":"Vaziri","year":"2006","journal-title":"Hemodial Int"},{"key":"B14","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1046\/j.1523-1755.2003.00803.x","article-title":"Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients","volume":"63","author":"Kalantar-Zadeh","year":"2003","journal-title":"Kidney Int"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/cells12121581","article-title":"The role of inflammation in CKD","volume":"12","author":"Kadatane","year":"2023","journal-title":"Cells"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000132474.50966.DA","article-title":"Endothelial dysfunction","volume":"15","author":"Endemann","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006080919","article-title":"Lipid changes and statins in chronic renal insufficiency","volume":"17","author":"Ritz","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1600-6135.2004.0355.x","article-title":"Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative","author":"Kasiske","year":"2004","journal-title":"Am J Transplant"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2014.107","article-title":"Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction","volume":"37","author":"Shibagaki","year":"2014","journal-title":"Hypertens Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"10734","DOI":"10.1038\/s41598-020-67026-1","article-title":"Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease","volume":"10","author":"Peng","year":"2020","journal-title":"Sci Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2019.06.016","article-title":"The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis","volume":"29","author":"Liu","year":"2019","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-018-1652-5","article-title":"The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5","volume":"23","author":"Liu","year":"2019","journal-title":"Clin Exp Nephrol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfx313","article-title":"Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study","volume":"33","author":"Chou","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"B25","article-title":"Allopurinol against progression of chronic kidney disease","volume":"11","author":"Golmohammadi","year":"2017","journal-title":"Iran J Kidney Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915833","article-title":"Effects of allopurinol on the progression of chronic kidney disease","volume":"382","author":"Badve","year":"2020","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1697","article-title":"Comparative renoprotective effect of febuxostat and allopurinol in predialysis stage 5 chronic kidney disease patients: A nationwide database analysis","volume":"107","author":"Hsu","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"B28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11657-015-0241-4","article-title":"Is allopurinol use associated with an excess risk of osteoporotic fracture? A National PreScription Registry study","volume":"10","author":"Dennison","year":"2015","journal-title":"Arch Osteoporos"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0800885","article-title":"Uric acid and cardiovascular risk","volume":"359","author":"Feig","year":"2008","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00273.x","article-title":"Hyperuricemia induces endothelial dysfunction","volume":"67","author":"Khosla","year":"2005","journal-title":"Kidney Int"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/08037050510008878","article-title":"Effects of allopurinol, a xanthineoxidase inhibitor, on renal injury in hypercholesterolemia-induced hypertensive rats","volume":"14","author":"Minami","year":"2005","journal-title":"BloodPressure"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2017.07.013","article-title":"Effect of allopurinol and uric acid normalization on serum lipids hyperuricemic subjects: A systematic review with meta-analysis","volume":"50","author":"Castro","year":"2017","journal-title":"Clin Biochem"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/nu16142324","article-title":"Effects of xanthine oxidase inhibition by febuxostat on lipid profiles of patients with hyperuricemia: insights from randomized PRIZE study","volume":"16","author":"Saito","year":"2024","journal-title":"Nutrients"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.791983","article-title":"Prevalence of hyperuricemia among chinese adults: findings from two nationally representative cross-sectional surveys in 2015\u201316 and 2018-19","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fneph.2025.1526182","article-title":"Efficacy of febuxostat on hyperuricemia and estimated glomerular filtration rate in patients with non-dialysis stage 3\/4 chronic kidney disease and assessment of cardiac function: a 12-month interventional study","volume":"5","author":"Waheed","year":"2025","journal-title":"Front Nephrol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000000886","article-title":"Effects of SGLT2 Inhibitors on Lower eGFR Decline in Non-Diabetic CKD Patients without Proteinuria","volume":"360","author":"Matsui","year":"2025","journal-title":"Kidney"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1042\/CS20160047","article-title":"Sex and gender differences in chronic kidney disease: progression to end-stage renal disease and haemodialysis","volume":"130","author":"Cobo","year":"2016","journal-title":"Clin Sci (London England: 1979)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.18.2404","article-title":"Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey","volume":"283","author":"Fang","year":"2000","journal-title":"JAMA"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1159\/000443769","article-title":"Hyperuricemia, cardiovascular disease, and hypertension","volume":"3","author":"Kuwabara","year":"2016","journal-title":"Pulse (Basel)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/1753-0407.12609","article-title":"Journal of diabetes: ushering in volume 10","volume":"10","author":"Bloomgarden","year":"2018","journal-title":"J Diabetes"},{"key":"B42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/ajh\/hpab067","article-title":"Differences in hypertension prevalence and hypertension control by urbanization among adults in the United States, 2013-2018","volume":"35","author":"Ostchega","year":"2022","journal-title":"Am J Hypertens"},{"key":"B43","volume-title":"Sample size tables for clinical studies","author":"Machin","year":"2009"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2004.04.011","article-title":"American Society of Echocardiography guidelines and standards for performance of the fetal echocardiogram","volume":"17","author":"Rychik","year":"2004","journal-title":"J Am Soc Echocardiogr"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2005.10.005","article-title":"Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology","volume":"18","author":"Lang","year":"2005","journal-title":"J Am Soc Echocardiogr"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.11.016","article-title":"Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial","volume":"65","author":"Goicoechea","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e16311","DOI":"10.1097\/MD.0000000000016311","article-title":"Effects of febuxostat on renal function in patients with chronic kidney disease: A systematic review and meta-analysis","volume":"98","author":"Lin","year":"2019","journal-title":"Med (Baltimore)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150067","article-title":"Effect of urate lowering therapy on renal disease progression in hyperuricemic patients with chronic kidney disease","volume":"42","author":"Kim","year":"2015","journal-title":"J Rheumatol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","article-title":"Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: A randomized trial","volume":"72","author":"Kimura","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.05.017","article-title":"Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: A 6-month, double-blind, randomized, placebo-controlled trial","volume":"66","author":"Sircar","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"B51","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5923\/j.ajb.20190902.01","article-title":"Comparative Study of Lipid Profile in Patients with Chronic Kidney Disease on Haemodialysis \/ Conservative Management with Control Population","volume":"9","author":"Muhammed Sanoop","year":"2019","journal-title":"Am J Biochem"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"139","author":"Levey","year":"2003","journal-title":"Ann Intern Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21506","article-title":"The study of pattern of lipid profile in chronic kidney disease patients on conservative management and hemodialysis: A comparative study","volume":"14","author":"Saini","year":"2022","journal-title":"Cureus"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1159\/000342390","article-title":"Serum uric acid independently predicts cardiovascular events in advanced nephropathy","volume":"36","author":"Kanbay","year":"2012","journal-title":"Am J Nephrol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2061","article-title":"Sex differences in lipid and lipoprotein metabolism: it's not just about sex hormones","volume":"96","author":"Wang","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.2174\/1381612822666160701073452","article-title":"Lipids, statins, and heart failure: an update","volume":"22","author":"Katsiki","year":"2016","journal-title":"Curr Pharm Des"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2021.09.011","article-title":"Inequalities in enrolment of women and racial minorities in trials testing uric acid lowering drugs","volume":"31","author":"Fogacci","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.890305","article-title":"Association between serum uric acid level and carotid atherosclerosis and metabolic syndrome in patients with type 2 diabetes mellitus","volume":"13","author":"Li","year":"2022","journal-title":"Front Endocrinol"}],"updated-by":[{"DOI":"10.3389\/fendo.2026.1788912","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000}}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1592290\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:40:51Z","timestamp":1771911651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1592290\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":58,"alternative-id":["10.3389\/fendo.2025.1592290"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1592290","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]},"article-number":"1592290"}}